30 años de energía saludable para toda la piel
Continuamos diseñando el futuro de la medicina estética
(1996-2005)
The Science Comes First
The laser industry had a skin tone problem.
We spent nearly a decade solving it - engineering 650-micropulse pulse technology that made safe treatments across all Fitzpatrick skin types possible for the first time.
We chose to be right, not first.
• 1996
Aerolase founded with a singular misson: create laser technology safe for all skin types.
• 2000
First FDA clearance.
• 2004
Expanded FDA clearances across multiple indications.
• 2005
LightPod Neo & LightPod Era platforms established.
Nine years. Zero shortcuts. The science was proven before commercial pressure ever entered the equation.
We expanded geographically before we expanded commercially.Validación global a través de la excelencia clínica.
• 2006–2011
U.S. dermatology market entry with clinical research and proof of concept.
• 2012–2015
Additional FDA clearances for Neo; Medical Advisory Board formed; peer-reviewed publications.
Every adoption was intentional. Every case study was a proof point.Dejamos que los resultados clínicos, no los presupuestos de marketing, impulsen la adopción. La tecnología demostró su eficacia en las condiciones más exigentes.
Nos expandimos geográficamente antes de expandirnos comercialmente, lo que nos permitió adoptar la KOL y crear estudios de casos en diversas poblaciones de pacientes de todo el mundo.
(2006-2015)
Demostrando que funciona en todas partes
We didn't chase volume — we chose our first customers as carefully as we'd chosen our technology. Clinical outcomes, not marketing budgets, drove adoption.
(2016-2021)
From Clinic to the World Stage
With clinical validation in hand, we expanded internationally and launched the next generation of laser platforms.
From proof of concept to product launch.
• 2016–2017
International expansion into Europe, the Middle East, Asia and Africa.
• 2018
Neo Elite, Era Elite and Neo V launched.
• 2019–2021
North America commerical infrastructure built out.
From Technology pioneer to market leader.
• 2022
Major sales expansion across North America , Exci308 added to the Aerolase technology portfolio, business plan to target Dermatologists, Plastic Surgeons, and Aestheticians.
• 2023
Australia market development, expanded KOL network across all specialties.
• 2024
Matured sales infrastructure and market segmentation, formalized customer success programs.
• 2025
Hybrid Fractional Era launched, Aerolase India established, Era Focus in development.
(2022-2025)
Building the Engine to Scale
The science was undeniable — now we built the commercial engine to match it.
(2026+)
The Confidence Era
Proving what 30 years of precision enables.
Three decades of physics-first innovation. One unwavering commitment: healthy energy that works for every patient, every time.
The Next 30 Years
We're not just celebrating where we've been. We're defining where the industry is going!
Tres décadas de impacto
Más de 3000
Prácticas atendidas.
1 M
Pacientes tratados.
Más de 25
Países a los que se llegó.
I-VI
Todos los fototipos tratados de forma segura.
30 Years, In Their Words
«Durante mucho tiempo, hemos buscado dispositivos que fueran seguros y eficaces para una variedad de tonos de piel. Para los pacientes de piel más oscura que buscan depilarse, rejuvenecerse, tratar los vasos sanguíneos o tener moretones, realmente no teníamos ese dispositivo hasta que apareció Aerolase. Es seguro y eficaz, y puedo usarlo en cualquier paciente».
